

Welcome to the SAGITTARIUS newsletter, the six-monthly appointment to be updated on the SAGITTARIUS project.

A foreword by the Study Chair

A promising impact

The SAGITTARIUS trial may demonstrate that some colon cancer patients can safely avoid chemotherapy and its adverse effects after surgery, either by using **personalized therapies** based on the molecular characteristics of the tumour or, always with medical supervision, by receiving no treatment at all. I am grateful to the patients who have already joined us, and to the clinical teams working tirelessly to bring this vision to life.

- Clara Montagut Viladot (Hospital del Mar - Parc de Salut Mar, Department of Medical Oncology, Barcelona)

Read the editorial

SAGITTARIUS latest news & events



The SAGITTARIUS trial is actively running!



25 out of 26 SAGITTARIUS centres are already activated!

Take a look at the list of SAGITTARIUS centres



More than 100 patients already enrolled in the trial! To obtain robust data, SAGITTARIUS experts need to include several hundreds patients. Find out how the clinical trial works and who

How does the SAGITTARIUS trial work?

Events we attended

21st January 2025 Training event - Liquid Biopsy to Guide Post-Surgical Precautionary Therapy of Colon and Rectal Cancer Milan

23th-25th January X Liquid Biopsy Symposium | Santiago de Compostela 2025

28th-29th January EORC webinar - Nucleic Acids (cfDNA/ctDNA): In use, 2025 in view and on the horizon | Online event

4th February 2025 Conference - Uno sguardo alla ricerca, uno sguardo al **futuro** ("Looking ahead, looking at the future") | Biella

mCRC Symposium - Results and implications of the 21st-22nd May 2025 AIRC 5 per mille metastatic colorectal cancer Program <u>Milan</u>

> The SAGITTARIUS project showcased through a poster at the American Society of Clinical Oncology Annual Meeting 2025

Under the spotlight

30th May-3rd June

2025

Several media outlets have highlighted the SAGITTARIUS project and its potential to improve patients' quality of life while reducing the socioeconomic burden of colon cancer across Europe.

- Fondamentale, Jan 2024
- Il Venerdì di La Repubblica, Feb 2024
- Libero Quotidiano, Mar 2024 • BioTech Spain, May 2024
- La Repubblica, Nov 2024 ANSA, Nov 2024 • Il Giornale, Nov 2024
- Financial Times, Dec 2024 • Virgilio.it, Jan 2025 • Il Sole 24 Ore, Feb 2025
- Radio News 24, Feb 2025 • Obiettivo salute - Radio24, Il Sole 24 Ore, Mar 2025



Upcoming SAGITTARIUS events

1st July 2025 **1st Consortium Meeting** | Barcelona

SAGITTARIUS Workshop on Liquid Biopsy | Barcelona 1st July 2025

2nd Annual Cluster Meeting | Berlin

Explore our updated website to discover **new sections**, **fresh** content, and valuable resources about the SAGITTARIUS project!

16th October 2025

SAGITTARIUS project

Stay updated about the

Having a common mission

Networking and collaborating for beating cancer

SAGITTARIUS fruitful collaboration in the framework of the European Cancer Mission Cluster on Diagnosis and Treatment continues, addressing together several issues related to the conduct of pragmatic clinical trials. We are 12 Horizon Europe projects with similar **objectives**; collectively, we aim to identify synergies to maximize the impact of our projects.

Find out more about the European Cancer Cluster

Meet the people behind SAGITTARIUS

Clara Montagut is Head of the Gastrointestinal Cancer Unit, in the Medical Oncology Department at Hospital Del Mar, in Barcelona.

> Watch Clara Montagut's presentation

Marco Pierotti is the CEO and Scientific Director of Cogentech, a Benefit corporation controlled by IFOM ETS that provides scientific and diagnostic services to researchers and clinicians.

Watch Marco Pierotti's





presentation

















Funded by the European Union programme Horizon Europe under Grant Agreement No 101104657.

Disclaimer: Funded by the European Union. However, the views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them.

*|IFNOT:ARCHIVE_PAGE|**|LIST:ADDRESSLINE|**|END:IF|* update your preferences or unsubscribe

